Categories
Change Password!
Reset Password!
In atopic dermatitis-affected children and adolescents, abrocitinib shows rapid and sustained improvements in symptoms.
In a first-of-its-kind real-world study, researchers have found that the Janus kinase (JAK1) inhibitor abrocitinib may offer an effective, safe, and well-tolerated treatment option for children and adolescents struggling with moderate-to-severe atopic dermatitis (AD). The prospective study, conducted across two centers, followed 28 pediatrics aged under 18, including those as young as 4 years. Participants were grouped by age (<6, 6–11, and 12–17 years) and managed with orally administered abrocitinib at doses of 25 mg, 50 mg, or 100 mg daily based on age and weight.
The treatment’s impact was evaluated at baseline and at weeks 2, 4, and 12 using multiple measures, including the Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), Investigator’s Global Assessment (IGA), Numerical Rating Scale (NRS) for itch, sleep-loss scores, and dermatology-specific quality of life tools. The results were notably positive. By week 12, 100% of patients achieved EASI-50, with 60.7% reaching EASI-75, and 25% attaining EASI-90.
Additionally, 57.2% achieved clear or almost clear skin (IGA 0/1), and 85.7% experienced a prominent reduction in itch intensity (≥4-point drop in NRS-itch). Improvements in quality of life and sleep issues were reported by over 78% of the cohort. Importantly, similar clinical responses were observed across all three age groups, including the youngest participants under 6 years of age. In terms of safety, only 2 adolescents (7.1%) experienced mild adverse events—one case of nausea and one of Kaposi’s varicelliform eruption.
No serious side effects were witnessed during the treatment period. As pediatric dermatologists seek more targeted and effective therapies, these results pave the way for further investigation—and potentially broader use—of abrocitinib in younger age groups.
Medicine
Effectiveness and safety of age-based dosing of abrocitinib in children and adolescents with moderate to severe atopic dermatitis: A two-center, prospective real-world study in China
Jingyao Liang et al.
Comments (0)